...We Welcome You to the Zenith Epigenetics Hub withIn The AGORACOM COMMUNITY!

Zenith's BET Inhibitor ZEN-3694 is Currently Being Evaluated in Multiple Oncology Clinical Trials

Free
Message: Zenith-Oncology Pipeline

KOO - I can't answer your query about why Agoracom doesn't post ZHCLF like they do RVXCF on the RVX board. I can only surmise it is because OTC isn't recognized as a real exchange and yet the do for RVX because it is also on the TSX so gets some cred there. Not sure!

Also, I queried IR about the Prommissory Note details like rate and maturity date but just got a reply refusing to give that info.

Share
New Message
Please login to post a reply